MatTek's EpiVaginal Excels in Microbicide/HIV Research Study
Posted on: Tuesday, 27 February 2007, 12:01 CST
ASHLAND, Mass., Feb. 27 /PRNewswire/ -- MatTek Corp. today announced that its patented EpiVaginal(TM) human cell-derived tissue model was successfully used in pre-clinical research investigating HIV infection and microbicide interaction.
According to the United Nations AIDS Program (UNAIDS), almost half of the adults living with HIV and AIDS are women. Over the past two years, the number of women infected with HIV has increased in every region of the world, with rates rising particularly rapidly in Eastern Europe, Asia, and Latin America. In sub-Saharan Africa, women already make up almost 60% of adults living with HIV, and heterosexual transmission of HIV is the dominant route of infection.
Because of this, major HIV prevention research is focused on the development of safe, socially acceptable and affordable microbicides for use by women, particularly in third world countries. Topically-applied microbicides provide protection against sexual transmission of HIV/AIDS and other infections.
University of Central Florida researchers, led by Dr. Alexander Cole, recently published their research on a novel microbicide in the journal "Immunology" (online edition). This pre-clinical research study used EpiVaginal tissues as a biologically relevant model in order to assess the toxicity of newly developed microbicides, and to evaluate the efficacy of microbicides in the prevention and transmission of HIV infection. From these results, it can also be predicted that utilization of EpiVaginal tissues can reduce the number of animals required to study toxicity and efficacy of newly developed, topically applied, women-related products and formulations.
Dr. Seyoum Ayehunie, Lead Scientist for MatTek's EpiVaginal products, stated, "We are pleased that EpiVaginal performed so well in this pre-clinical microbicide research study. Our goal is to provide HIV researchers with a more human-like, non-animal test platform, and EpiVaginal provided that for Dr. Cole's research team."
Research details are available on the MatTek Web site: http://www.mattek.com/
About MatTek -- MatTek Corp., founded in 1985, is an industry leader in tissue engineering. MatTek produces human cell-derived, 3-D, ready-to-use in vitro tissue models for use in product development, claims substantiation, safety assessment, and drug discovery/development applications in the Pharmaceutical, Biotech, Cosmetics, Personal Care, Household Products and Chemicals industries, as well as in academic and government research labs.
MatTek Corp.
CONTACT: Dave Ingalls, Sales & Marketing Manager, MatTek Corp.,+1-508-881-6771 X225, or dingalls@mattek.com
Web site: http://www.mattek.com/
Source: PRNewswire
Related Articles
- Bioniche Presents Pre-Clinical Research at Two International Conferences
- Response Genetics, Inc. Announced Results of Pre-Clinical Studies on Gene Expression at the American Association for Cancer Research 2008 Annual Meeting
- CardioVascular BioTherapeutics Completes Pre-Clinical Stroke Research
- VGX Pharmaceuticals' Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
- Medistem Laboratories Commences Pre-Clinical Research With Indiana University School of Medicine's Center for Vascular Biology and Medicine Using Cord Blood in the Treatment of Critical Limb Ischemia
- Alnylam and Collaborators Present Pre-Clinical Data for RNAi Therapeutics for the Treatment of Respiratory Diseases Including Pandemic Influenza; Results Include Data on Anti-Viral Activity of RNAi Therapeutics Toward H5N1 Virus
- EPIX Pharmaceuticals Pre-Clinical Research Program Optioned for Development
- Enzo Biochem Says Pre-Clinical Study Suggests Small Molecule Compound Could Spur Bone Growth; Results Presented at Bone and Mineral Research Conference
- Marc Pharmaceuticals Announces Positive Pre-Clinical HIV Results
 |
 |
User Comments (0)
RSS Feeds